2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 119

Mitochondrial Transplantation Suppressed Muscle Inflammation and Improved the Mitochondrial Dysfunction in C Protein-induced Myositis Model
Abstract Number: 120

Administration of a CD45 Antibody Drug Conjugate as a Novel, Targeted Approach to Achieve Immune System Reset: A Single Dose of CD45-targeted ADC Safely Conditions for Autologous Transplant and Ameliorates Disease in Multiple Models of Autoimmune Disease
Abstract Number: 121

In Vitro Human Enthesitis Model with Induced IL-17A and TNFα from CD4+ and CD8+ T Cells and Effect of Pharmacological Antagonism with Janus Kinase and Retinoic Acid Receptor-related Orphan Receptor γ Inhibition
Abstract Number: 122

Inhibition of Necroptosis Suppresses Muscle Cell Death and Inflammatory Infiltrate, and Improves Muscle Strength in Experimental Polymyositis
Abstract Number: 123

Blockade of Antigen-specific T Cell Activation by a Non-Depleting Anti-HLA-DR Monoclonal Antibody with a Unique Binding Epitope
Abstract Number: 124

Treatment with Abatacept but Not with TNF Blockers, Is Associated with a Reduction of Constitutively Elevated Circulating Follicular Helper T Cells in Rheumatoid Arthritis
Abstract Number: 125

Elevated Proliferative Capacity of CD8+ T Cells in Giant Cell Arteritis
Abstract Number: 126

Antibodies Targeting Mitochondrial Antigens Are Associated with Reduced Thrombotic Events in APS
Abstract Number: 127

Elevated Levels of the Neutrophil Extracellular Trap-binding Protein LILRA3 in Primary Antiphospholipid Syndrome
Abstract Number: 128

Metabolomics Analysis Identifies Biomarkers for APS and Suggests a Potential New Pathway Related to APS Pathogenesis
Abstract Number: 129

Surface Proteins on Exosomes Derived from Plasma of APS Patients Indicate an Altered Immune, Cell Adhesion and Coagulation Profile
Abstract Number: 130

Is There Clinically Relevant Plasma Interference with ELISA Detection of APS Antibodies? Reproducibility of Serum and Plasma Testing in a Real-World Clinical Setting
Abstract Number: 131

Anti-Phosphatidylserine Prothrombin Antibodies as a Predictor of the LAC in an All-Comer Population
Abstract Number: 132

Anti-phosphatidylserine/prothrombin Antibodies Confer a Distinctive Molecular Profile in Primary Antiphospholipid Syndrome Patients
Abstract Number: 133

Anti-β2GPI Domain 1 Antibodies Stratify High Risk of Thrombosis and Pregnancy Morbidity in a Large Cohort of Chinese Patients with Antiphospholipid Syndrome

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.